ReviewHuman vaccines & immunotherapeutics2017
Vaccine development and trials in low and lower-middle income countries: Key issues, advances and future opportunities.
Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Descriptions of risks and benefits of HIV vaccine trials in low-and middle-income countries (LMICs): an integrative review.BMC medical ethics · 2025Pooled it
- Parental motivations, facilitators, and barriers to participating in a pediatric vaccine trial in Kathmandu, Nepal: A qualitative study.Human vaccines & immunotherapeutics · 2026Article
- One Health Perspective on the EnterotoxigenicMicroorganisms · 2026Review
- The long-term impact of vaccine clinical research on national stakeholders involved: Experience from a low-income Country.Human vaccines & immunotherapeutics · 2025Article
- Developing an advanced course of vaccinology in middle-income countries: The case of China.Biosafety and health · 2024Article
- Strategies to Prevent Early and Late-Onset Group BPathogens (Basel, Switzerland) · 2023Review
- COVID-19 site readiness initiative: Building clinical trial capacity for vaccine efficacy trials in Latin America in response to the pandemic.Vaccine: X · 2022Article
- Factors affecting willingness to participate in vaccine clinical trials in an underdeveloped country: perspective from Nepal.Human vaccines & immunotherapeutics · 2022Article
- Article
- COVID-19 vaccinology landscape in Africa.Frontiers in immunology · 2022Article
- Safety surveillance and challenges in accelerated COVID-19 vaccine development.Therapeutic advances in drug safety · 2022Review
- Evidence-Based Approach to One Health Vaccinology.Archives of Razi Institute · 2021Article
- Evolving pharmacovigilance requirements with novel vaccines and vaccine components.BMJ global health · 2021Review
- COVID-19 immunity and vaccines: what a pharmacist needs to know.Asian biomedicine : research, reviews and news · 2021Review
- Using maternal and neonatal data collection systems for coronavirus disease 2019 (COVID-19) vaccines active safety surveillance in low- and middle-income countries: an international modified Delphi study.Gates open research · 2021Article
- Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review).International journal of molecular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 10 years there has been an increase in the number of vaccine clinical studies conducted in resource limited countries. These include vaccine trials for diseases such as malaria and dengue fever which are endemic to many low and lower-middle income countries. Concurrent with the increase in the number of trials, has been the increase and improvement in local infrastructure to enable the appropriate conduct and oversight of trials in these settings, including strengthening of local scientific capabilities, ethical and regulatory oversight. While significant advances have been made, there remain gaps to be addressed including strengthening pharmacovigilance in these regions. There are also opportunities to establish novel collaborations to address diseases specific to these populations including strengthening local manufacturers, new ways to engage established large pharmaceutical companies and leveraging established global infrastructure and pathways to develop innovative products beyond vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.